Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

KV9.1 Inhibitors

KV9.1 inhibitors represent a class of chemical compounds that selectively target the KV9.1 potassium channel, which is part of the larger family of voltage-gated potassium (KV) channels. The KV9.1 subunit belongs to the electrically silent KV subfamily, meaning that while it does not form functional potassium channels by itself, it can co-assemble with other subunits, such as those from the KV2 family, to modulate their function. These inhibitors work by blocking or reducing the activity of the heteromeric channels that are formed by the combination of KV9.1 with other subunits. The blockade of these channels can lead to alterations in potassium ion flux, which is critical in maintaining the resting membrane potential and in regulating action potential dynamics in excitable cells. The modulation of KV9.1-containing channels can influence cell membrane excitability, thereby affecting various physiological processes where potassium currents play a crucial role.

In terms of chemical diversity, KV9.1 inhibitors encompass a wide range of molecular structures, from small organic molecules to more complex ligands. The inhibitors often interact with the channel in a voltage-dependent manner, meaning their binding and efficacy can vary depending on the membrane potential of the cell. These compounds can bind to specific regions of the channel, including the pore domain or other regulatory sites that influence the gating mechanism. Structural studies of these inhibitors have shown that many of them can induce conformational changes in the channel, leading to either partial or complete inhibition of potassium ion flow. Research into KV9.1 inhibitors continues to explore their precise binding affinities, kinetic properties, and structural characteristics, with a focus on understanding how these interactions modulate the biophysical properties of KV9.1-containing channels.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

This DNA methyltransferase inhibitor could cause hypomethylation of the KCNS1 gene's promoter, potentially leading to repression of transcription factors specific to KV9.1 expression.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

As a histone deacetylase inhibitor, Trichostatin A could lead to chromatin remodeling, resulting in the decreased accessibility of transcriptional machinery to the KCNS1 gene, thereby reducing KV9.1 synthesis.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

This mTOR inhibitor could downregulate protein synthesis pathways, leading to a global reduction in protein synthesis, including the decrease of KV9.1 channel subunit production.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

By interfering with lysosomal acidification, Chloroquine could prevent the proper processing and degradation of transcriptional regulators, reducing the expression of target genes including KCNS1.

Spironolactone

52-01-7sc-204294
50 mg
$107.00
3
(1)

This aldosterone receptor antagonist could decrease the transcription of aldosterone-responsive elements within the KCNS1 promoter region, leading to reduced KV9.1 channel expression.

Verapamil

52-53-9sc-507373
1 g
$367.00
(0)

By blocking L-type calcium channels, Verapamil could decrease intracellular calcium signals that are necessary for the transcriptional activation of the KCNS1 gene.

5,5-Diphenyl Hydantoin

57-41-0sc-210385
5 g
$70.00
(0)

This anticonvulsant could lead to the hyperpolarization of neuronal membranes, decreasing the neuronal activity-dependent transcriptional triggers required for KV9.1 expression.

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$76.00
$150.00
$725.00
$1385.00
$2050.00
73
(3)

By elevating intracellular cAMP levels, Forskolin could lead to a downregulation of cAMP-responsive genes, potentially including the downregulation of KCNS1 transcription.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$36.00
$68.00
$107.00
$214.00
$234.00
$862.00
$1968.00
47
(1)

This polyphenol could suppress the activation of certain transcription factors, leading to a targeted reduction in the transcriptional initiation of the KCNS1 gene, and thus less KV9.1 production.

Lithium

7439-93-2sc-252954
50 g
$214.00
(0)

This GSK-3 inhibitor could disrupt signal transduction pathways necessary for the initiation of KCNS1 gene transcription, resulting in decreased KV9.1 expression.